CALIFORNIA
|
000-23125
|
330238801
|
(STATE
OR OTHER JURISDICTION OF INCORPORATION)
|
(COMMISSION
FILE NUMBER)
|
(IRS
EMPLOYER IDENTIFICATION
NO.)
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR
240.13e-4(c))
|
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d)
|
Exhibits
|
Exhibit99.1:
|
Press
Release of Spacelabs Healthcare, Inc., dated September 11,
2007.
|
OSI
SYSTEMS, INC.
|
||
Date:
September 11, 2007
|
||
By:
|
/s/
Alan Edrick
|
|
Alan
Edrick
|
||
Chief
Financial Officer
|
Number
|
Description
|
Press
Release of Spacelabs Healthcare, Inc., dated September 11,
2007.
|
|
·
|
Revenue
up 6% to $233.2 million (FY 2006: $220.6 million). Excluding revenues
attributable to Del Mar Reynolds (“DMR”), acquired in July 2006,
underlying revenues decreased by approximately 6% compared to fiscal
2006.
|
|
·
|
Gross
profit margin decreased 1.4% to 46.6% (FY 2006:
48.0%).
|
|
·
|
Net
income decreased 55% to $3.8 million (FY 2006: $8.4 million); includes
impairment, restructuring and other charges of approximately $3.0
million
and favorable settlement of lawsuit with GE Finland Oy resulting
in
one-time gain of approximately $14.4
million.
|
|
·
|
The
Company experienced a rebound in the critical North American patient
monitoring business in the fourth quarter of this fiscal
year. During the fourth quarter the Company experienced record
bookings while also recording underlying organic revenue growth of
approximately 8%.
|
|
·
|
Cash
and cash equivalents $4.4 million as of June 30, 2007 compared to
$8.8
million as of June 30, 2006.
|
|
·
|
Completed
integration and global review of cost structure resulting in approximately
$10 million of annualized savings. Cost saving measures
included:
|
|
o
|
Consolidation
of 5 facilities;
|
|
o
|
Global
headcount reduction of approximately
8%;
|
|
o
|
Divested
non-core product lines.
|
|
·
|
In
July 2006 the Company acquired Del Mar Reynolds, expanding its
product portfolio to include diagnostic cardiology solutions while
expanding operational presence in the European market and doubling
the
size of its Clinical Trials
Business.
|
|
·
|
The
Company remained committed to R&D and expanding its product portfolio;
FY 2007 expenditure was $25.1 million (FY 2006: $19.1 million). In
fiscal
2007 the Company launched a number of new products, including the
following highlighted
introductions:
|
|
o
|
In
July 2006, the Company announced the launch of seven new state-of-the-art
Precision Pressure Control VentilationTM
ventilators
to its existing anesthesia product
line;
|
|
o
|
In
October 2006, the Company launched its advanced anesthesia system,
BleaseSirius™ and UltraviewSL Perioperative Monitoring Suite in
the North American market;
|
|
o
|
In
November 2006, the Company announced the launch of its first vital
signs
monitor targeted specifically at the day surgery center and emerging
markets, the MCare 3000;
|
|
o
|
In
March 2007, the Company introduced two diagnostic cardiology products,
the
evo Digital Holter Recorder and Voyager 12-Lead Electrocardiogram
(“ECG”)
system; and
|
|
o
|
In
March 2007, the Company received FDA 510k clearance to distribute
its new
Cardiology Data Management system, Sentinel in the
U.S.
|
|
·
|
In
July 2006, Mr. Dave Tilley was appointed as a Director and Mr. Nikhil
Mehta was appointed as Chief Financial Officer replacing Mr. Ralph
Hunter
who had resigned to pursue other professional
opportunities.
|
|
·
|
The
Company expanded its presence in the emerging markets with the leasing
of
a new manufacturing facility in China. The facility is expected to
begin
operations in the second half of fiscal
2008.
|
|
·
|
During
the fiscal year, the Company received two awards from Frost &
Sullivan. In October 2006, the Company was named the North American
Patient Monitoring Company of the Year for 2006 and then in June
2007 the
Company received the 2007 Excellence in Technology
Award.
|
Nikhil
Mehta, Chief Financial Officer
|
Tel:
+1 310 349 2237
|
Jeremy
Norton, Director, Investor Relations
|
Tel:
+1 310 717 9182
|
Piper
Jaffray
|
|
David
Rasouly
|
Tel:
+ 44 203 142 8700
|
|
o
|
In
July 2006, the Company announced the launch of seven new state-of-the-art
Precision Pressure Control VentilationTM
ventilators
to its existing anesthesia product
line;
|
|
o
|
In
October 2006, the Company launched its advanced anesthesia system,
BleaseSirius™ and UltraviewSL Perioperative Monitoring Suite in
the North American market;
|
|
o
|
In
November 2006, the Company announced the launch of its first vital
signs
monitor targeted specifically at the day surgery center and emerging
markets, the MCare 3000;
|
|
o
|
In
March 2007, the Company introduced two diagnostic cardiology products,
the
evo Digital Holter Recorder and Voyager 12-Lead Electrocardiogram
(“ECG”)
system; and
|
|
o
|
In
March 2007, the Company received FDA 510k clearance to distribute
its new
Cardiology Data Management system, Sentinel in the
U.S.
|
June
30,
|
||||||||
ASSETS
|
2007
|
2006
|
||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ |
4,392
|
$ |
8,809
|
||||
Accounts
receivable, net of allowance for doubtful accounts of $1,552 and
$1,412 at
June 30, 2007 and 2006, respectively
|
69,199
|
64,505
|
||||||
Other
receivables
|
2,085
|
2,140
|
||||||
Inventories
|
30,654
|
33,043
|
||||||
Prepaid
expenses and other current assets
|
2,748
|
2,338
|
||||||
Deferred
income taxes
|
11,477
|
4,925
|
||||||
Total
current assets
|
120,555
|
115,760
|
||||||
Property,
plant and equipment, net
|
13,057
|
10,280
|
||||||
Goodwill
|
26,442
|
5,990
|
||||||
Intangible
assets, net
|
23,510
|
17,556
|
||||||
Other
assets
|
722
|
1,518
|
||||||
Total
assets
|
$ |
184,286
|
$ |
151,104
|
||||
LIABILITIES
AND SHAREHOLDERS’ EQUITY
|
||||||||
Current
liabilities:
|
||||||||
Revolving
line of credit
|
$ |
9,275
|
$ |
-
|
||||
Current
portion of long-term debt and capital leases
|
4,361
|
-
|
||||||
Accounts
payable
|
20,419
|
17,875
|
||||||
Accrued
payroll and related expenses
|
6,269
|
6,363
|
||||||
Deferred
revenue
|
5,252
|
3,482
|
||||||
Accrued
warranties
|
3,349
|
3,397
|
||||||
Income
taxes payable
|
11,946
|
9,706
|
||||||
Payables
to related parties
|
6,150
|
13,360
|
||||||
Other
accrued expenses and current liabilities
|
13,126
|
9,118
|
||||||
Total
current liabilities
|
80,147
|
63,301
|
||||||
Loan
from OSI
|
13,951
|
31,810
|
||||||
Long-term
debt and capital leases, less current portion
|
18,410
|
-
|
||||||
Deferred
rent
|
5,174
|
5,379
|
||||||
Deferred
income taxes
|
6,507
|
296
|
||||||
Other
long-term liabilities
|
1,881
|
1,339
|
||||||
Total
liabilities
|
126,070
|
102,125
|
||||||
Commitments
and contingencies (Note 6 and 9)
|
-
|
-
|
||||||
Shareholders’
equity:
|
||||||||
Preferred
stock, $0.001 par value - 10,000 shares authorized, none
issued
|
-
|
-
|
||||||
Common
stock, $0.001 par value - 250,000,000 shares authorized, 68,099,442
and
67,855,234 shares issued and outstanding at June 30, 2007 and 2006,
respectively
|
68
|
68
|
||||||
Additional
paid-in capital
|
45,452
|
41,306
|
||||||
Retained
earnings
|
11,410
|
7,609
|
||||||
Accumulated
other comprehensive income (loss)
|
1,286
|
(4 | ) | |||||
Total
shareholders’ equity
|
58,216
|
48,979
|
||||||
Total
liabilities and shareholders’ equity
|
$ |
184,286
|
$ |
151,104
|
Year
ended June 30,
|
||||||||
2007
|
2006
|
|||||||
Revenues
|
$ |
233,181
|
$ |
220,627
|
||||
Cost
of goods sold
|
124,596
|
114,739
|
||||||
Gross
profit
|
108,585
|
105,888
|
||||||
Operating
expenses:
|
||||||||
Selling,
general and administrative
|
85,260
|
72,587
|
||||||
Research
and development
|
25,055
|
19,098
|
||||||
Impairment,
restructuring and other charges
|
2,991
|
624
|
||||||
Total
operating expenses
|
113,306
|
92,309
|
||||||
Income
(loss) from operations
|
(4,721 | ) |
13,579
|
|||||
Interest
expense – loan from OSI
|
1,815
|
1,384
|
||||||
Interest
expense – other
|
2,375
|
1
|
||||||
Interest
income
|
(138 | ) | (177 | ) | ||||
Other
income, net
|
(14,451 | ) | (805 | ) | ||||
Income
before provision for income taxes
|
5,678
|
13,176
|
||||||
Provision
for income taxes
|
1,877
|
4,799
|
||||||
Net
income
|
$ |
3,801
|
$ |
8,377
|
||||
Earnings
per share:
|
||||||||
Basic
|
$ |
0.06
|
$ |
0.13
|
||||
Diluted
|
$ |
0.06
|
$ |
0.13
|
||||
Shares
used in per share calculation:
|
||||||||
Basic
|
67,981
|
63,574
|
||||||
Diluted
|
69,053
|
64,732
|
Number
of shares
|
Common
Stock
|
Additional
Paid-in Capital
|
Combined
Parent’s Investment
|
Retained
Earnings (Deficit)
|
Accumulated
Other Comprehen-sive Income (Loss)
|
Total
Share-holders’ Equity
|
||||||||||||||||||||||
Balance,
July 1, 2005
|
-
|
-
|
-
|
$ |
13,544
|
$ | (768 | ) | $ | (706 | ) | $ |
12,070
|
|||||||||||||||
Comprehensive
income:
|
||||||||||||||||||||||||||||
Net
income
|
8,377
|
8,377
|
||||||||||||||||||||||||||
Reclassification
of realized gain on available-for-sale securities, net of
tax
|
(108 | ) | (108 | ) | ||||||||||||||||||||||||
Foreign
currency translation
|
793
|
793
|
||||||||||||||||||||||||||
Unrealized
gain on available- for-sale securities, net of tax
|
17
|
17
|
||||||||||||||||||||||||||
Total
comprehensive income
|
9,079
|
|||||||||||||||||||||||||||
Stock
transfers
|
54,390
|
55
|
13,489
|
(13,544 | ) |
-
|
||||||||||||||||||||||
Stock
compensation expense
|
1,551
|
1,551
|
||||||||||||||||||||||||||
Public
offering of common stock, net of expenses of $3,451
|
13,465
|
13
|
26,266
|
26,279
|
||||||||||||||||||||||||
Balance,
June 30, 2006
|
67,855
|
68
|
41,306
|
-
|
7,609
|
(4 | ) |
48,979
|
||||||||||||||||||||
Comprehensive
income:
|
||||||||||||||||||||||||||||
Net
income
|
3,801
|
3,801
|
||||||||||||||||||||||||||
Foreign
currency translation
|
1,404
|
1,404
|
||||||||||||||||||||||||||
Reclassification
of realized gain on available-for-sale securities, net of
tax
|
(17 | ) | (17 | ) | ||||||||||||||||||||||||
Other
|
(97 | ) | (97 | ) | ||||||||||||||||||||||||
Total
comprehensive income
|
5,091
|
|||||||||||||||||||||||||||
Stock
compensation expense
|
1,570
|
1,570
|
||||||||||||||||||||||||||
Exercise
of stock options
|
244
|
208
|
208
|
|||||||||||||||||||||||||
Push-down
of goodwill from OSI
|
2,368
|
2,368
|
||||||||||||||||||||||||||
Balance,
June 30, 2007
|
68,099
|
68
|
45,452
|
-
|
11,410
|
1,286
|
58,216
|
Year
ended June 30,
|
||||||||
2007
|
2006
|
|||||||
CASH
FLOW FROM OPERATING ACTIVITIES:
|
||||||||
Net
income
|
$ |
3,801
|
$ |
8,377
|
||||
Adjustments
to reconcile net income to net cash provided by operating
activities:
|
||||||||
Depreciation
and amortization
|
7,591
|
4,489
|
||||||
Deferred
income taxes
|
(2,174 | ) | (2,075 | ) | ||||
Loss
(gain) on sale of assets
|
144
|
(280 | ) | |||||
Unrealized
loss (gain) on foreign exchange contract
|
24
|
(475 | ) | |||||
Stock
compensation expense
|
1,570
|
1,551
|
||||||
Write
off of in-process research and development
|
556
|
-
|
||||||
Other
|
(357 | ) | (87 | ) | ||||
Changes
in operating assets and liabilities, net of business
acquisition:
|
||||||||
Accounts
receivable
|
638
|
(19,630 | ) | |||||
Other
receivables
|
1,232
|
(1,142 | ) | |||||
Inventories,
net
|
5,032
|
5,862
|
||||||
Prepaid
expenses and other current assets
|
160
|
12
|
||||||
Accounts
payable
|
(774 | ) | (1,407 | ) | ||||
Accrued
payroll and related expenses
|
(505 | ) | (858 | ) | ||||
Deferred
revenue
|
(647 | ) | (152 | ) | ||||
Accrued
warranties
|
(925 | ) | (361 | ) | ||||
Income
taxes payable
|
3,529
|
5,637
|
||||||
Payables
to related parties, net
|
(6,354 | ) |
4,177
|
|||||
Other
accrued expenses and current liabilities
|
(1,437 | ) |
2,198
|
|||||
Net
cash provided by operating activities
|
11,104
|
5,836
|
||||||
CASH
FLOW FROM INVESTING ACTIVITIES:
|
||||||||
Additions
to property, plant and equipment
|
(5,839 | ) | (5,132 | ) | ||||
Proceeds
from sale of marketable securities
|
147
|
922
|
||||||
Cash
paid for Del Mar Reynolds acquisition, net of cash
acquired
|
(22,139 | ) |
-
|
|||||
Other
|
(303 | ) | (380 | ) | ||||
Net
cash used in investing activities
|
(28,134 | ) | (4,590 | ) | ||||
CASH
FLOW FROM FINANCING ACTIVITIES:
|
||||||||
Loan
repayments to OSI
|
(16,900 | ) | (25,500 | ) | ||||
Net
proceeds from public offering of common stock
|
-
|
26,279
|
||||||
Proceeds
from term loan
|
25,412
|
-
|
||||||
Repayments
of term loan
|
(3,630 | ) |
-
|
|||||
Net
borrowings under revolving line of credit
|
9,275
|
-
|
||||||
Repayments
of other long-term debt and capital leases
|
(976 | ) |
-
|
|||||
Stock
options exercised
|
208
|
-
|
||||||
Other
|
80
|
-
|
||||||
Net
cash provided by financing activities
|
13,469
|
779
|
||||||
EFFECT
OF EXCHANGE RATE CHANGES ON CASH
|
(856 | ) | (1,091 | ) | ||||
NET
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
(4,417 | ) |
934
|
|||||
CASH
AND CASH EQUIVALENTS, BEGINNING OF YEAR
|
8,809
|
7,875
|
||||||
CASH
AND CASH EQUIVALENTS, END OF YEAR
|
$ |
4,392
|
$ |
8,809
|
June
30,
|
||||||||
2007
|
2006
|
|||||||
North
America
|
64%
|
75%
|
||||||
Europe
|
24
|
15
|
||||||
Asia
– Pacific
|
3
|
3
|
||||||
Other
|
9
|
7
|
||||||
100%
|
100%
|
|||||||
Year
ended June 30,
|
||||||||
2007
|
2006
|
|||||||
Net
income
|
$ |
3,801
|
$ |
8,377
|
||||
Weighted
average shares outstanding -- basic
|
67,981
|
63,574
|
||||||
Dilutive
effect of stock options
|
1,072
|
1,158
|
||||||
Weighted
average shares outstanding -- diluted
|
69,053
|
64,732
|
||||||
Basic
earnings per share
|
$ |
0.06
|
$ |
0.13
|
||||
Diluted
earnings per share
|
$ |
0.06
|
$ |
0.13
|
Cash
paid for common stock, net of cash acquired
|
$ |
24,911
|
||
Less
refund pursuant to working capital adjustment
|
(1,694 | ) | ||
Less
refund pursuant to 13-month revenue and earnings
adjustment
|
(1,872 | ) | ||
Direct
costs
|
794
|
|||
Total
purchase price
|
$ |
22,139
|
Net
liabilities acquired
|
$ | (3,197 | ) | |
In-process
research and development costs acquired
|
561
|
|||
Identifiable
intangible assets acquired
|
7,567
|
|||
Goodwill
|
17,208
|
|||
$ |
22,139
|
Revenue
|
$ |
253,761
|
||
Income
before income taxes
|
$ |
10,264
|
||
Net
income
|
$ |
6,525
|
||
Earnings
per share (basic and diluted)
|
$ |
0.10
|
June
30,
|
||||||||
2007
|
2006
|
|||||||
Raw
materials and components
|
$ |
13,470
|
$ |
15,627
|
||||
Work
in process
|
455
|
971
|
||||||
Finished
goods
|
6,569
|
6,555
|
||||||
Demonstration
inventories
|
3,775
|
3,746
|
||||||
Customer
service inventories
|
6,385
|
6,144
|
||||||
Total
|
$ |
30,654
|
$ |
33,043
|
Estimated
|
June
30,
|
||||||||
Useful
Lives
|
2007
|
2006
|
|||||||
Equipment
|
4-8
years
|
$ |
8,922
|
$ |
6,101
|
||||
Leasehold
improvements
|
3-10
years
|
1,450
|
1,336
|
||||||
Tooling
|
3-5
years
|
1,259
|
1,719
|
||||||
Furniture
and fixtures
|
4-10
years
|
2,177
|
1,554
|
||||||
Computer
equipment and software
|
3-5
years
|
8,956
|
5,951
|
||||||
Vehicles
|
3-5
years
|
286
|
57
|
||||||
23,050
|
16,718
|
||||||||
Less
accumulated depreciation and amortization
|
(9,993 | ) | (6,438 | ) | |||||
Total
|
$ |
13,057
|
$ |
10,280
|
Balance
as of July 1, 2005
|
$ |
5,853
|
||
Foreign
currency translation adjustment
|
137
|
|||
Balance
as of June 30, 2006
|
5,990
|
|||
Goodwill
recorded during the period
|
20,099
|
|||
Foreign
currency translation adjustment
|
353
|
|||
Balance
as of June 30, 2007
|
$ |
26,442
|
June
30, 2007
|
June
30, 2006
|
|||||||||||||||||||||||
Carrying
Value
|
Accumulated
Amortization
|
Intangibles,
Net
|
Carrying
Value
|
Accumulated
Amortization
|
Intangibles,
Net
|
|||||||||||||||||||
Core
technology
|
$ |
8,364
|
$ |
2,496
|
$ |
5,868
|
$ |
8,153
|
$ |
1,629
|
$ |
6,524
|
||||||||||||
Customer
relationships/backlog
|
7,267
|
1,834
|
5,433
|
4,027
|
892
|
3,135
|
||||||||||||||||||
Software
development costs
|
1,208
|
1,134
|
74
|
1,998
|
1,441
|
557
|
||||||||||||||||||
Patents
|
388
|
211
|
177
|
417
|
199
|
218
|
||||||||||||||||||
Developed
technology
|
5,461
|
725
|
4,736
|
150
|
148
|
2
|
||||||||||||||||||
Intangibles,
subject to amortization
|
22,688
|
6,400
|
16,288
|
14,745
|
4,309
|
10,436
|
||||||||||||||||||
Tradenames,
not amortized
|
7,222
|
-
|
7,222
|
7,120
|
-
|
7,120
|
||||||||||||||||||
Total
intangibles
|
$ |
29,910
|
$ |
6,400
|
$ |
23,510
|
$ |
21,865
|
$ |
4,309
|
$ |
17,556
|
Weighted
|
|
Average
Lives
|
|
Core
technology
|
10
years
|
Customer
relationships/backlog
|
9.5
years
|
Software
development costs
|
5
years
|
Patents
|
11
years
|
Developed
technology
|
5
years
|
Tradenames
|
Indefinite
|
2008
|
$ |
2,635
|
||
2009
|
2,561
|
|||
2010
|
2,561
|
|||
2011
|
2,561
|
|||
2012
|
2,561
|
|||
2013
and thereafter
|
3,409
|
|||
$ |
16,288
|
June
30,
|
||||||||
2007
|
2006
|
|||||||
Sales
returns reserve
|
$ |
4,038
|
$ |
3,501
|
||||
Accrued
commissions
|
1,899
|
2,387
|
||||||
Customer
advances
|
1,405
|
852
|
||||||
State
and local taxes
|
1,482
|
494
|
||||||
Restructuring
accrual
|
201
|
−
|
||||||
Other
|
4,101
|
1,884
|
||||||
Total
|
$ |
13,126
|
$ |
9,118
|
Balance
as of July 1, 2006
|
$ |
−
|
||
Employee
termination costs expensed during the year
|
1,304
|
|||
Facility
closure costs expensed during the year
|
82
|
|||
Total
expensed
|
1,386
|
|||
Paid
during the year
|
(1,185 | ) | ||
Restructuring
accrual balance as of June 30, 2007
|
$ |
201
|
Five-year
term loan due in 2011
|
$ |
21,782
|
||
Capital
leases and other
|
989
|
|||
22,771
|
||||
Less
current portion of long-term debt
|
(4,361 | ) | ||
Total
long-term debt
|
$ |
18,410
|
2008
|
$ |
4,361
|
||
2009
|
3,869
|
|||
2010
|
3,650
|
|||
2011
|
10,891
|
|||
$ |
22,771
|
June
30,
|
||||||||
2007
|
2006
|
|||||||
United
States
|
$ |
6,847
|
$ |
12,994
|
||||
Foreign
|
(1,169 | ) |
182
|
|||||
Total
pre-tax income
|
$ |
5,678
|
$ |
13,176
|
June
30,
|
||||||||
2007
|
2006
|
|||||||
Current:
|
||||||||
Federal
|
$ |
1,157
|
$ |
6,217
|
||||
State
|
264
|
321
|
||||||
Foreign
|
464
|
473
|
||||||
1,885
|
7,011
|
|||||||
Change
in valuation allowance
|
−
|
(137 | ) | |||||
Deferred
|
(8 | ) | (2,075 | ) | ||||
Total
provision for income taxes
|
$ |
1,877
|
$ |
4,799
|
June
30,
|
||||||||
2007
|
2006
|
|||||||
Deferred
income tax assets:
|
||||||||
Net
operating loss carryforwards
|
$ |
4,263
|
$ |
2,688
|
||||
Inventory
capitalization
|
2,127
|
1,463
|
||||||
Accrued
bonuses
|
267
|
332
|
||||||
Inventory
reserves
|
1,755
|
1,067
|
||||||
Accrued
warranty
|
1,176
|
765
|
||||||
Bad
debt reserves
|
508
|
405
|
||||||
Inter-company
profits
|
1,201
|
850
|
||||||
Sales
returns allowance
|
142
|
158
|
||||||
Accrued
vacation
|
601
|
460
|
||||||
Deferred
rent
|
1,923
|
852
|
||||||
Other
|
1,997
|
1,134
|
||||||
Total
deferred income tax assets
|
15,960
|
10,174
|
||||||
Valuation
allowance
|
(2,448 | ) | (1,434 | ) | ||||
Net
deferred income tax assets
|
13,512
|
8,740
|
||||||
Deferred
income tax liabilities:
|
||||||||
Depreciation
|
(1,372 | ) | (1,518 | ) | ||||
Intangible
assets
|
(6,899 | ) | (1,833 | ) | ||||
Other
|
(271 | ) | (760 | ) | ||||
Total
deferred income tax liabilities
|
(8,542 | ) | (4,111 | ) | ||||
Net
deferred income tax assets
|
$ |
4,970
|
$ |
4,629
|
||||
Net
deferred income tax assets – current
|
$ |
11,477
|
4,925
|
|||||
Net
deferred income tax liability – non-current
|
(6,507 | ) | (296 | ) | ||||
$ |
4,970
|
$ |
4,629
|
June
30, 2007
|
June
30, 2006
|
|||||||||||||||
US
dollars
|
%
|
US
dollars
|
%
|
|||||||||||||
Provision
for income taxes at US federal statutory rate
|
$ |
1,987
|
35.0
|
$ |
4,610
|
35.0
|
||||||||||
State
income taxes, net of federal benefit
|
264
|
4.6
|
318
|
2.4
|
||||||||||||
Research
and development tax credits
|
(546 | ) | (9.6 | ) | (88 | ) | (0.7 | ) | ||||||||
Foreign
income subject to tax at other than U.S. federal Statutory
rate
|
(182 | ) | (3.2 | ) |
27
|
0.2
|
||||||||||
Non-deductible
expenses
|
354
|
6.3
|
243
|
1.8
|
||||||||||||
Domestic
Production tax benefit
|
−
|
−
|
(174 | ) | (1.3 | ) | ||||||||||
Changes
in valuation allowance
|
−
|
−
|
(137 | ) | (1.0 | ) | ||||||||||
$ |
1,877
|
33.1
|
$ |
4,799
|
36.4
|
Balance
as of July 1, 2005
|
$ |
3,706
|
||
Additions
- charged to cost of sales
|
2,531
|
|||
Reductions
for warranty repair costs
|
(2,840 | ) | ||
Balance
as of June 30, 2006
|
3,397
|
|||
Additions
- charged to cost of sales
|
2,624
|
|||
Increases
as a result of Del Mar Reynolds acquisition
|
439
|
|||
Reductions
for warranty repair costs
|
(3,111 | ) | ||
Balance
as of June 30, 2007
|
$ |
3,349
|
2008
|
$ |
7,521
|
||
2009
|
6,636
|
|||
2010
|
5,786
|
|||
2011
|
5,153
|
|||
2012
|
4,838
|
|||
2013
and thereafter
|
11,696
|
|||
$ |
41,630
|
Year
ended June 30,
|
||||||||
2007
|
2006
|
|||||||
Cost
of goods sold
|
$ |
176
|
$ |
233
|
||||
Selling,
general and administrative
|
1,291
|
1,192
|
||||||
Research
and development
|
103
|
126
|
||||||
Stock
based compensation expense before taxes
|
1,570
|
1,551
|
||||||
Related
income tax benefit
|
(518 | ) | (565 | ) | ||||
Stock
based compensation, net of estimated taxes
|
$ |
1,052
|
$ |
986
|
June
30,
|
||||||||
2007
|
2006
|
|||||||
Expected
dividend
|
0%
|
0%
|
||||||
Risk-free
interest rate
|
4.5%
|
4.6%
|
||||||
Expected
volatility
|
37.8%
|
44.2%
|
||||||
Expected
life (in years)
|
3.6
|
3.6
|
Number
of Options
|
Weighted-
Average Exercise Price
|
Weighted-
Average Remaining Contractual Term (in years)
|
Aggregate
Intrinsic Value ($000)
|
|||||||||||||
Outstanding
– July 1, 2005
|
-
|
|||||||||||||||
Granted
|
390,000
|
$ |
2.46
|
|||||||||||||
Converted
into Plan
|
5,215,452
|
1.29
|
||||||||||||||
Exercised
|
(2,543 | ) |
1.05
|
|||||||||||||
Canceled
|
(128,790 | ) |
1.14
|
|||||||||||||
Outstanding
– June 30, 2006
|
5,474,119
|
$ |
1.37
|
3.3
|
$ |
5,290
|
||||||||||
Granted
|
997,200
|
2.11
|
||||||||||||||
Exercised
|
(282,682 | ) |
1.10
|
|||||||||||||
Canceled
|
(327,087 | ) |
1.43
|
|||||||||||||
Outstanding
– June 30, 2007
|
5,861,550
|
$ |
1.50
|
2.7
|
$ |
1,096
|
||||||||||
Exercisable
– June 30, 2007
|
3,294,545
|
$ |
1.23
|
2.1
|
$ |
955
|
Expected
dividend
|
0%
|
|||
Risk-free
interest rate
|
3.3%
|
|||
Expected
volatility
|
51.0%
|
|||
Expected
life (in years)
|
3.6
|
Number
of Options
|
Weighted-
Average Exercise Price
|
Weighted-
Average Remaining Contractual Term (in years)
|
Aggregate
Intrinsic Value ($000)
|
||||||||||
Outstanding
– July 1, 2005
|
7,923,500
|
$ |
0.70
|
||||||||||
Granted
|
739,000
|
1.10
|
|||||||||||
Converted
into Plan
|
1,065,680
|
0.58
|
|||||||||||
Exercised
|
-
|
-
|
|||||||||||
Canceled
|
(242,559 | ) |
0.70
|
||||||||||
Converted
out of Plan
|
(9,485,621 | ) |
0.72
|
||||||||||
Outstanding
– June 30, 2006
|
-
|
$ |
-
|
$ |
-
|
||||||||
Exercisable
– June 30, 2006
|
-
|
$ |
-
|
$ |
-
|
Equipment,
Services & Supplies
|
Clinical
Trial Services
|
Total
|
||||||||||
Year
ended June 30, 2006:
|
||||||||||||
External
customers revenue
|
$ |
215,377
|
$ |
5,250
|
$ |
220,627
|
||||||
Income
(loss) from operations
|
$ |
14,157
|
$ | (578 | ) | $ |
13,579
|
|||||
Goodwill
|
$ |
5,990
|
$ |
−
|
$ |
5,990
|
||||||
Total
assets
|
$ |
147,104
|
$ |
4,000
|
$ |
151,104
|
||||||
Capital
expenditures
|
$ |
3,408
|
$ |
1,724
|
$ |
5,132
|
||||||
Depreciation
and amortization expense
|
$ |
4,276
|
$ |
213
|
$ |
4,489
|
||||||
Year
ended June 30, 2007:
|
||||||||||||
External
customers revenue
|
$ |
222,892
|
$ |
10,289
|
$ |
233,181
|
||||||
Loss
from operations
|
$ | (4,226 | ) | $ | (495 | ) | $ | (4,721 | ) | |||
Goodwill
|
$ |
26,442
|
$ |
−
|
$ |
26,442
|
||||||
Total
assets
|
$ |
178,483
|
$ |
5,803
|
$ |
184,286
|
||||||
Capital
expenditures
|
$ |
4,269
|
$ |
1,570
|
$ |
5,839
|
||||||
Depreciation
and amortization expense
|
$ |
6,576
|
$ |
1,015
|
$ |
7,591
|
United
States
|
Foreign
|
Total
|
||||||||||
Year
ended June 30, 2006:
|
||||||||||||
Capital
equipment
|
$ |
113,501
|
$ |
52,705
|
$ |
166,206
|
||||||
Service,
spare parts, supplies and accessories
|
35,556
|
18,865
|
54,421
|
|||||||||
Total
revenue
|
$ |
149,057
|
$ |
71,570
|
$ |
220,627
|
||||||
Year
ended June 30, 2007:
|
||||||||||||
Capital
equipment
|
$ |
99,364
|
$ |
67,805
|
$ |
167,169
|
||||||
Service,
spare parts, supplies and accessories
|
36,551
|
29,461
|
66,012
|
|||||||||
Total
revenue
|
$ |
135,915
|
$ |
97,266
|
$ |
233,181
|
June
30,
|
||||||||
2007
|
2006
|
|||||||
United
States
|
$ |
34,948
|
$ |
24,583
|
||||
United
Kingdom
|
28,149
|
8,899
|
||||||
Foreign –
Other
|
634
|
1,862
|
||||||
Total
long-lived assets
|
$ |
63,731
|
$ |
35,344
|
2007
|
2006
|
|||||||
Interest
paid
|
$ |
2,295
|
$ |
1,306
|
||||
Taxes
paid
|
$ |
552
|
$ |
1,183
|
||||
Unrealized
gain on marketable securities
|
$ |
-
|
$ |
26
|
||||
Non-cash
Investing and Financing Activities:
|
||||||||
Goodwill
contributed by OSI from share repurchases
|
$ |
2,368
|
$ |
-
|
||||
Sale
of Osteometer to OSI in exchange for reduction of OSI Loan
|
$ |
961
|
$ |
-
|
||||
Capital
expenditures in payables
|
$ |
970
|
$ |
-
|